Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

ARIPIPRAZOLE

All products: general benefit

Other products in the same Health Canada class (N05A, N05AX) — coverage varies; not interchangeable

  • Brexpiprazole (Rexulti): general benefit
  • Cariprazine (Vraylar): general benefit
  • Paliperidone (Invega): general benefit
  • Paliperidone palmitate (Invega Sustenna): general benefit
  • Risperidone (Risperdal): general benefit, Not a benefit
  • Asenapine (Saphris): general benefit

18 more in the class list below

Abilify · DIN 02322404 · 15mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists Abilify (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Abilify · DIN 02322404 Manufacturer: Otsuka Pharmaceutical Co. Ltd.; listing date 2011-10-25 Health Canada: Marketed since 2018-06-05 · brand ABILIFY · ATC N05AX12 ARIPIPRAZOLE · form Tablet · route Oral · ingredients ARIPIPRAZOLE 15 MG · company Otsuka pharmaceutical co ltd · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $1.2692 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80785 · Verify on the e-Formulary ↗ (DIN 02322404)

Source record
DIN 02322404: Abilify Raw flags: sec3=Y Item: 281608304; group id 478; item number 1213; lccId None; manufacturer id OTS Source form: Tab; strength: 15mg Recorded listing: General benefit Source prices (unrounded): $5.1985; ministry $1.2692 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02322404 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80785 Therapeutic Notes (formulary) Notes: Subject to the specific drug's product monograph, for the treatment of schizophrenia and related psychotic disorders after failure, intolerance or contraindication to at least one less expensive antipsychotic alternative. Not indicated for the treatment of dementia or dementia-related behavioral problems in the elderly. Prescribers should be informed and stay current with a drug's official indications in accordance with Health Canada's approved product monograph.
Interchangeable products
Apo-Aripiprazole · DIN 02471116 · $1.2692 Aripiprazole · DIN 02506734 · $1.2692 Aripiprazole · DIN 02534355 · $1.2692 Auro-Aripiprazole · DIN 02460068 · $1.2692 Jamp Aripiprazole · DIN 02553201 · $1.2692 Mint-Aripiprazole · DIN 02483580 · $1.2692 NRA-Aripiprazole · DIN 02472252 · $1.2692 PMS-Aripiprazole · DIN 02466678 · $1.2692 Sandoz Aripiprazole · DIN 02473682 · $1.2692 Teva-Aripiprazole · DIN 02464179 · $1.2692
Shortage status: resolved shortage (ended 2021-10-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02322404
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (28:16:08 Tranquilizers) and how they are covered

Matched class: 28:16:08 Tranquilizers

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ASENAPINE, BREXPIPRAZOLE, CARIPRAZINE, FLUPENTIXOL DECANOATE, FLUPENTIXOL DIHYDROCHLORIDE, PALIPERIDONE, PALIPERIDONE PALMITATE, PERICYAZINE, PIMOZIDE, ZIPRASIDONE HCL MONOHYDRATE, ZUCLOPENTHIXOL DECANOATE, ZUCLOPENTHIXOL DIHYDROCHLORIDE Some products covered without a code (check the product listing): ALPRAZOLAM, BROMAZEPAM, CHLORDIAZEPOXIDE, CHLORPROMAZINE, CLORAZEPATE DIPOTASSIUM, DIAZEPAM, FLUPHENAZINE HCL, HALOPERIDOL, HALOPERIDOL DECANOATE, LORAZEPAM, LOXAPINE SUCCINATE, LURASIDONE HYDROCHLORIDE, OLANZAPINE, OXAZEPAM, PERPHENAZINE, PROCHLORPERAZINE, QUETIAPINE, RISPERIDONE, TRIFLUOPERAZINE 28:16:08 Tranquilizers

BREXPIPRAZOLE

· 6 products · General benefit · strengths: 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg · Tab

CARIPRAZINE

· 4 products · General benefit · strengths: 1.5mg, 3mg, 4.5mg, 6mg · Cap

PALIPERIDONE

· 3 products · General benefit · strengths: 3mg, 6mg, 9mg · ER Tab

PALIPERIDONE PALMITATE

· 8 products · General benefit · strengths: 50mg, 75mg, 100mg, 150mg, 175mg/0.875mL, 263mg/1.315mL, 350mg/1.75mL, 525mg/2.625mL · Inj Pref Syr, Inj Susp-Pref Syr

RISPERIDONE

· 82 products · Listed, not a benefit (12), General benefit (70) · strengths: 1mg/mL, 0.5mg, 1mg, 2mg, 3mg, 4mg, 25mg, 37.5mg, 50mg, 0.25mg · O/L, Orally Disintegrating Tab, Pd for Inj-Vial Pk, Tab

ASENAPINE

· 2 products · General benefit · strengths: 5mg, 10mg · SL Tab

CHLORPROMAZINE

· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 25mg, 50mg, 100mg · Tab

FLUPENTIXOL DECANOATE

· 2 products · General benefit · strengths: 20mg/mL, 100mg/mL · Inj Sol-1mL Amp Pk

FLUPENTIXOL DIHYDROCHLORIDE

· 2 products · General benefit · strengths: 0.5mg, 3mg · Tab

FLUPHENAZINE HCL

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 1mg, 2mg, 5mg · Tab

HALOPERIDOL

· 14 products · Listed, not a benefit (7), General benefit (7) · strengths: 5mg/mL, 0.5mg, 1mg, 2mg, 5mg, 10mg, 20mg · Inj Sol-1mL Pk, Tab

LOXAPINE SUCCINATE

· 8 products · Listed, not a benefit (4), General benefit (4) · strengths: 5mg, 10mg, 25mg, 50mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:08 and 21 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: manic or mixed episodes in bipolar i disorder, schizophrenia and related psychotic disorders
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: PALIPERIDONE, ZIPRASIDONE HCL MONOHYDRATE OLANZAPINE · General benefit (99), Off-Formulary Interchangeable, not an ODB benefit (17) Indications ZYPREXA, ZYPREXA ZYDIS (oral olanzapine) is indicated for • the acute and maintenance treatment of schizophrenia and related psychotic disorders. PM: https://pdf.hres.ca/dpd_pm/00085079.PDF; date 2026-06-16; DIN 02229250; fetched 2026-09-10 Product monograph ZYPREXA, ZYPREXA ZYDIS (oral olanzapine) is indicated for • the acute treatment of manic or mixed episodes in bipolar I disorder (monotherapy or cotherapy) • maintenance treatment in bipolar I disorder (monotherapy). PM: https://pdf.hres.ca/dpd_pm/00085079.PDF; date 2026-06-16; DIN 02229250; fetched 2026-09-10 Product monograph PALIPERIDONE · General benefit 1 INDICATIONS INVEGA® (paliperidone) is indicated for the treatment of schizophrenia and related psychotic disorders. PM: https://pdf.hres.ca/dpd_pm/00059282.PDF; date December 17, 2020; DIN 02300273; fetched 2026-09-10 Product monograph RISPERIDONE · Listed, not a benefit (12), General benefit (70) 1 INDICATIONS Adults Schizophrenia pms-RISPERIDONE (risperidone) is indicated for the acute treatment and maintenance treatment of schizophrenia and related psychotic disorders. PM: https://pdf.hres.ca/dpd_pm/00062538.PDF; date August 13, 2021; DIN 02252007; fetched 2026-09-10 Product monograph ZIPRASIDONE HCL MONOHYDRATE · General benefit 1 INDICATIONS  Schizophrenia ZELDOX (ziprasidone) is indicated for the treatment of schizophrenia and related psychotic disorders. PM: https://pdf.hres.ca/dpd_pm/00072509.PDF; date SEP 15, 2023; DIN 02298597; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS ABILIFY (aripiprazole) is indicated for:  the treatment of schizophrenia and related psychotic disorders in adults. In controlled clinical trials, ABILIFY was found to improve both positive and negative symptoms. ABILIFY has been shown to be more effective than placebo in maintaining clinical improvement for up to 26 weeks in adults.  the treatment of manic or mixed episodes in bipolar I disorder in adults. ABILIFY may be used as acute monotherapy or cotherapy with lithium or divalproex sodium when there is an insufficient acute response to these agents alone. ABILIFY as cotherapy with lithium or divalproex sodium has been shown to be more effective than placebo plus mood stabilizer in maintaining clinical improvement for up to 1 year in adult patients with manic or mixed episodes associated with bipolar I disorder (see CLINICAL TRIALS, Trial Design and Study Demographics, Bipolar Disorder). The physician who elects to use ABILIFY for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.  use as an adjunct to antidepressants for the treatment of Major Depressive Disor… https://pdf.hres.ca/dpd_pm/00060025.PDF PM date: February 11, 2021 Source product: ABILIFY; DIN 02322374; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.